Virus_Cells_Large.jpg
addiction-71538_640.jpg
Nano_Vision.jpg
PeptineoOffices.jpg
Virus_Cells_Large.jpg

About Us


SCROLL DOWN

About Us


Who we are

With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering.  By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including "tunable" nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins.  To that end, Peptineo is developing solutions that reflect research efforts in computer science, systems biology, physics, molecular biology, pharmacology, protein engineering and biotechnology.  The employees of Peptineo believe that by having a broad range of technology and scientific expertise, Peptineo will have the resources required to efficiently address current or evolving clinical demands. 

addiction-71538_640.jpg

Marketplace Challenges


Challenges faced in the development of new drugs for Pharma

SCROLL DOWN

Marketplace Challenges


Challenges faced in the development of new drugs for Pharma

Problems Faced by Pharma

In today’s market for pharmaceuticals, drugs that follow traditional design principles continue to fail at the critical step of clinical trials due to toxicity. In many cases, this can be attributed to non-specific interactions in the body.  However, even if a drug does complete clinical trials, its indication for usage is often adjusted to limit risks associated with these same safety concerns and to minimize downstream implications for future liability. 

At present, the following represent key challenges that have an unmet need in the drug delivery industry:

  • Poor solubility
  • Systemic drug toxicity
  • Immune response
  • Drug accumulation and poor elimination
  • Poor circulation times and half-life
  • Patent protection
Nano_Vision.jpg

We Partner to Make Medicine Safer...


Acetalated Dextran (Ac-DEX) for Drug Delivery Applications.  Scroll down for brief video that describes Ac-DEX, its history, and use for therapeutic applications.

SCROLL DOWN

We Partner to Make Medicine Safer...


Acetalated Dextran (Ac-DEX) for Drug Delivery Applications.  Scroll down for brief video that describes Ac-DEX, its history, and use for therapeutic applications.

Our Approach

Peptineo is working to commercialize a novel nanomaterial, acetalated dextran (Ac-DEX), for tunable, controlled release drug delivery applications. This elegant technology was developed in the world famous lab of Jean Fréchet, PhD. Subsequently, the technology continued to be developed by one of its key inventors Eric Bachelder, PhD - with breakthrough innovations employing the technology being led by Kristy Ainslie, PhD. Most notably, this technology was employed as part of the recent high profile DARPA vaccine challenge -which was targeted against an unknown pathogen. Of note, Dr. Bachelder and Dr. Ainslie have now joined Peptineo as key scientific advisors.

Peptineo is now working to demonstrate that the over US$10M invested in research & development of Ac-DEX has produced a disruptive, breakthrough solution for drug delivery challenges faced in modern medicine.

PeptineoOffices.jpg

Our Team


SCROLL DOWN

Our Team


Sheldon Jordan, PhD

President & Chief Executive Officer

Progressive leadership experience in government, semiconductor,  aerospace, and education/research sectors.  Managed engineering development and production activities with target contract values up to US$130 Million.

Leads overall company strategy, technology, marketing and vision.

Wojciech Ornatowski, PhD

Vice President, Research

Domain expertise in autophagy, neuroscience, pathogens, recombinant biology, instrumentation and mammalian cell line development. 

Leads company research & development and contract research activities.

Kimberley Beauford, MA

Vice President, Human Capital

Healthcare & Accounting industry veteran, business owner,  and entrepreneur.

Leads company human resource efforts.